Analysis of Immune Response In Bacterial Infection of Obese Subject
NCT ID: NCT02882568
Last Updated: 2017-12-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
15 participants
INTERVENTIONAL
2014-08-31
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
investigational
Blood test for Inflammatory and immunological analysis during acute sepsis phase and one month later
blood analysis
Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood analysis
Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* obesity: BMI \> 30
* presumed bacterial infection:
* pneumonitis (documented or probably)
* pyelonephritis / acute prostatitis
* soft tissue / skin infection (except for bedsore)
* cholecystitis / angiocholitis
* meningitis
* clostridium colitis
* surgical site infection
* signed consent
Exclusion Criteria
* patients with bacterial infection with treatment\> 4 weeks (ex. endocarditis; osteo- articular infections)
* patients with prior antibiotic treatment (\< 14 days)
* intensive care unit patients
* patients with a history of cancer or malignant hematological disease within the 5 previous years that is currently clinically significant (non metastatic prostatic and basocellular malignancy are excluded)
* patients with systemic disease
* Known diagnosis of human immunodeficiency infection (DICV, HIV…)
* immunosuppression treatment during last month including corticotherapy
* pregnancy
* 3 months follow up not possible
* non signed consent
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Versailles Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Roderick Meckenstock
Dr
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ch de Versailles
Le Chesnay, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
P15/19_ARIIBO
Identifier Type: -
Identifier Source: org_study_id